Farr M, Kitas G D, Waterhouse L, Jubb R, Felix-Davies D, Bacon P A
Department of Rheumatology, University of Birmingham.
Br J Rheumatol. 1990 Feb;29(1):46-9. doi: 10.1093/rheumatology/29.1.46.
Sulphasalazine (SASP) is now accepted as an effective slow-acting antirheumatic drug for treating active rheumatoid arthritis (RA), but has not been previously evaluated in psoriatic arthritis. An earlier open study suggested that it was well tolerated and potentially beneficial. The present double-blind placebo-controlled trial of 30 patients has now confirmed its efficacy. Greater improvement occurred in those patients on active treatment than on placebo, with more benefit being detected in those patients with the symmetrical polyarticular but seronegative pattern of arthritis associated with a high acute-phase response. SASP was stopped in 26% because of side-effects but these were mild. No exacerbation or remission of psoriasis was observed. Further studies are in progress to determine the degree of efficacy of SASP in different clinical subgroups of psoriatic arthritis.
柳氮磺胺吡啶（SASP）目前被公认为是治疗活动性类风湿关节炎（RA）的一种有效的慢作用抗风湿药物，但此前尚未在银屑病关节炎中进行评估。一项较早的开放性研究表明，它耐受性良好且可能有益。目前这项针对30名患者的双盲安慰剂对照试验现已证实了其疗效。接受积极治疗的患者比接受安慰剂治疗的患者改善更大，在那些患有对称性多关节但血清学阴性的关节炎且急性期反应较高的患者中发现了更多益处。26%的患者因副作用停用了SASP，但这些副作用很轻微。未观察到银屑病的加重或缓解。正在进行进一步研究以确定SASP在银屑病关节炎不同临床亚组中的疗效程度。
